Form 8-K Akero Therapeutics, Inc. For: Oct 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Form 8-K Akero Therapeutics, Inc. For: Oct 10
October 10, 2023 12:35 PM EDT
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).
The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More
October 10, 2023 8:26 AM EDT
Shares Akero Therapeutics (NASDAQ: AKRO) declined after it reported analysis of data from its study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The stock declined as much as 60% shortly after the data release.
The drug missed its primary endpoint but efficacy trends were positive in a tough population, and the selloff in shares could be an overreaction, said analysts at Cantor Fitzgerald.
Canaccord Genuity analysts said they would be strong buyers... More
October 10, 2023 8:21 AM EDT
Canaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More
